

JUN 24 2002
PATENT TRIAL WORK OFFICE

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing.
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

CHECK BOX, if applicable:
☒ DUPLICATE

Address to:

Assistant Commissioner for Patents
Box CPA
Washington, DC 20231

Attorney Docket No.
of Prior Application

146.1275

First Named Inventor

F. MAKISHMINA

Examiner Name

EV068843702 US

Group Art Unit

1646

Express Mail Label No.

D. Romeo

#31
A.9
7/8/02

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d),
(continued prosecution application (CPA)) of prior application number 08 / 945 459
filed on 10/20/97, entitled NOVEL PROTEIN AND PROCESS FOR PREPARING THE SAME

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office (Apr. 11, 2000).

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

1. ☐ Enter the unentered amendment previously filed on _____
TRANSMEL 00000003 0895459 116 in the prior nonprovisional application.
2. ☒ A preliminary amendment is enclosed.
1390.00 OP
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
710.00 OP
216.00 OP
 - a. ☐ DELETE the following inventor(s) named in the prior nonprovisional application:
.....
 - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
 - a. ☐ PTO-1449
 - b. ☐ Copies of IDS Citations

07/08/2002
01 FC:118
02 FC:131
03 FC:103

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c) or (j))		32 -20* =	12	x \$ 18 =	\$ 216
INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))		3 -3** =	0	x \$ 0 =	0
MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))				+ \$ 0 =	0
				BASIC FEE (37 CFR 1.16)	740.00
				Total of above Calculations =	\$ 956.00
Reduction by 50% for filing by small entity (Note 37 CFR 1.27).					
* Reissue claims in excess of 20 and over original patent. ** Reissue independent claims over original patent.				TOTAL =	\$ 956.00

6. ☐ Small entity status: Applicant claims small entity status. See 37 CFR 1.27.
7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 02 - 2275.
- a. ☒ Fees required under 37 CFR 1.16.
- b. ☐ Fees required under 37 CFR 1.17.
- c. ☐ Fees required under 37 CFR 1.18.
8. ☐ A check in the amount of \$ _____ is enclosed.
9. ☒ Payment by credit card. Form PTO-2038 is attached.
10. ☐ Applicant requests suspension of action under 37 CFR 1.103(b) for a period of _____ months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.
11. ☐ New Attorney Docket Number, if desired _____
[Prior application Attorney Docket Number will carryover to this CPA unless a new Attorney Docket Number has been provided herein.]
12. a. ☐ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)
- b. ☒ Return Receipt Postcard (Should be specifically itemized, See MPEP 503)
13. ☐ Other: _____

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

14. NEW CORRESPONDENCE ADDRESS


☐ Customer Number or Bar Code Label

or ☐ New correspondence address below

(Insert Customer No. or Attach bar code label here)

Name	Bierman, Muserlian and Lucas				
Address	600 Third Avenue				
City	New York	Slate	N.Y.	Zip Code	10016
Country	U.S.A.	Telephone	212-661-8000	Fax	661-8002

15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print IType)	Charles A. Muserlian
Signature	
Registration No. (Attorney/Agent)	19,683
Date	June 24, 2002



146.1275

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : D. Romeo
F. MAKISHMINA et al :
Serial No.: 945,459 : Group: 1646
Filed: October 20, 1997 :
For: NOVEL PROTEIN...THE SAME :

600 Third Avenue
New York, N.Y. 10016
June 24, 2002

RECEIVED
JUN 27 2002
TECH CENTER 1600/2900

AMENDMENT

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the office action of June 28, 2001, please amend
this application as follows:

IN THE CLAIMS:

31 Sub H
Claim 17 (amended) An isolated protein consisting of the 119
amino acids as shown in SEQ ID No: 1 free of proteins of SEQ ID No:
1, with an Ala or Met and Ala at the N-terminus.

32
Claim 20 (amended) A pharmaceutical composition comprising an
amount of the protein of claim 18 effective to treat cartilage
and/or bone diseases and a pharmaceutical carrier.

33
Claim 45 (amended) A pharmaceutical composition of claim 20
comprising natural or artificial bone.

34
Claim 48 (twice amended) The method of claim 34 wherein said
cartilage and/or bone diseases are chondrodysplasia,
chondrohypoplasia, chondrogenesis, palatoschisis and
osteodysplasia.